Growth Factors & Signaling

GHRP-2 (Pralmorelin)

For Research Use Only. Not for Human or Veterinary Use.

Overview

GHRP-2 (Growth Hormone Releasing Peptide-2, also called Pralmorelin) is a synthetic hexapeptide ghrelin-receptor agonist and one of the most potent GH-releasing peptides. Its D-amino-acid content gives it stability and potency, and it has been used both in preclinical work and as a diagnostic probe of growth-hormone reserve. It is a research compound.

Chemical Profile

PropertyValue
CAS number158861-67-7 (free base)
ClassHexapeptide GHSR-1a agonist
Amino-acid sequenceH-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂
Molecular formulaC₄₅H₅₅N₉O₆
Molecular weight≈ 817.9 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
GHRP-2 at a glance
Class
Hexapeptide GHSR-1a agonist
Other name
Pralmorelin
Research status
Clinical research (GH diagnostic, catabolic states)
Study routes
Subcutaneous, intravenous
Half-life
≈ 30 min
Key feature
One of the most potent GHRP agonists

Mechanism of Action

GHRP-2 is a potent GHSR-1a agonist. Its several D-amino acids resist proteolysis and give it high potency, and it produces a strong GH pulse. It raises prolactin somewhat more than the highly selective Ipamorelin, but less than the first-generation GHRP-6.

ComponentDetail
Primary targetGHSR-1a (ghrelin receptor)
PotencyAmong the highest of the GHRPs
G-protein couplingGαq/11 → PLC → IP₃ → Ca²⁺
GH releaseStrong pulse amplification
ProlactinMild elevation (less than GHRP-6)
CortisolMinimal at low levels

Pharmacology

ParameterValue
Half-life (t½)≈ 30 min (plasma)
Bioavailability (SC)≈ 70–80%
Time to peak (Tmax)≈ 15–20 min
MetabolismProteolytic degradation
Route of administrationSubcutaneous, intravenous
EliminationRenal (peptide fragments)

Research Evidence

Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.

Study typeResearch focusReference
Pituitary / animal modelsPotent GH pulse amplificationBowers CY, et al.
Human GH-stimulation testingGH-reserve diagnostic useGHRP-2 clinical literature
Catabolic-state researchGH/IGF-1 responsesGH-secretagogue literature

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Strong GH pulse amplification (high potency)pituitary / animal modelsBowers CY et al.
Used as a GH-reserve diagnostic probehuman GH-stimulation testingGHRP-2 clinical literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 100–300 µg per injection, in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~2–4 weeks
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
Local tolerabilityMild injection-site reactions
Prolactin / cortisolMild prolactin rise; minimal cortisol at low levels
AppetiteModerate (ghrelin-receptor effect)
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble
logP≈ −1.2 (hydrophilic)
pH (reconstituted)5.0–6.5
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

GHRP-2 is a C-terminally amidated hexapeptide made by Fmoc solid-phase synthesis. The D-alanine, D-2-naphthylalanine and D-phenylalanine residues need their dedicated D-configured building blocks.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinRink amide resin (C-terminal amide)
Special residuesD-Ala, D-2-Nal, D-Phe
CouplingHBTU / HOBt with DIPEA
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. Tryptophan is light-sensitive; confirm the D-configured residues.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, reversed-phase TFA/ACN gradientSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 818 Da
MALDI-TOFMass confirmation[M+H]⁺ ≈ 818 Da
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 818 Da). Tryptophan is light-sensitive; confirm the D-configured residues.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: Tryptophan is light-sensitive; confirm the D-configured residues.

Selected References

  • Bowers CY. Growth-hormone-releasing peptide (GHRP) research (foundational literature).
  • GHRP-2 / pralmorelin GH-stimulation-test clinical literature.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need GHRP-2 — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote